Drug intelligence / Profile preview

MLN-33

Development stage: Preclinical
Lead developer: CNBX Pharmaceuticals
Modality: Small Molecules

Overview

**MLN-33** is a proprietary synthetic cannabinoid drug candidate developed by CNBX Pharmaceuticals for the treatment of melanoma. It represents part of a cannabinoid-based pipeline targeting various cancers, leveraging a unique mechanism to potentially reduce tumor volume with low side effects as an early intervention therapy. The drug is in preclinical development, with plans to complete Pre-IND studies by the end of 2023, building on preclinical data supporting its efficacy in oncology applications.[3][5]

Beyond the preview

Go deeper on MLN-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLN-33.

Explore the full profile